GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

H.C. Wainwright 22nd Annual Global Investment Conference – Virtual Conference

GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital

GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update

GenSight Biologics obtains a €7m non-dilutive loan and renegotiates the bond agreement with Kreos Capital extending runway to mid-2021

GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020

KOL Call on LUMEVOQ® for the Treatment of Leber Hereditary Optic Neuropathy (LHON)

BIO 2020, San Diego (CA), US – Digital

GenSight Biologics will hold its General Meeting on April 29, 2020 behind closed doors

GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update